Recommended Topic Related To:

Noctec

"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...

Noctec

PATIENT INFORMATION

Chloral hydrate may cause gastrointestinal upset. The syrup should be diluted in half a glass of water or fruit juice.

Chloral hydrate may cause drowsiness; therefore, patients should be instructed to use caution when driving, operating dangerous machinery, or performing any hazardous task.

Patients should avoid alcohol and other CNS depressants. They should also be informed that chloral hydrate may be be habit-forming.

Chloral hydrate and all drugs should be kept out of the reach of children.

Patients should be warned against sudden discontinuation of chloral hydrate except under the advice of a Physician; they should also be informed of symptoms that would suggest potential adverse effects.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD